Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.3852W HIGH $14.76
Volume
140.58 K
Value Traded
67.58 M
Short % Float
12.44%
+0.23%Week
-18.94%1 Month
-29.12%3 Month
-25.79%6 Month
-84.99%5 Year
+1,431.49%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.72 B
EPS (TTM)
-2.74
P/E Ratio
-
Ent. Value
3.49 B
Total Shares
199.39 M
Float Shares
197.66 M
Insiders
0.85%
Institutions
114.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
XRAY Catalyst Timeline
Dated clinical, regulatory and corporate events for DENTSPLY SIRONA Inc.
Past FDA Catalysts and PDUFA Decisions
How XRAY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2003-12-19 | Oraqix (lidocaine) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
DENTSPLY SIRONA Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every XRAY program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HOSEIN CLYDEDirector | Buy | 6,500 70,575.456 held | $9.99 | 06/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XRAY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.5 % | 4.00 M | 100.00 K |
XRAY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XRAY ranks across every disease it competes in
Competitive Position is a premium feature
See how XRAY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXRAY News
XRAY▲ +0.3%today
Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement
Dentsply Sirona has announced an expanded partnership with Midwest Dental Equipment & Supply, effective November 1, 2026. This agreement allows Midwest Dental to offer Dentsply Sirona's technology portfolio, enhancing access to digital dentistry solutions. The collaboration aims to strengthen market coverage and support the adoption of connected technology solutions in dental practices across North America.
Read more →XRAYDentsply Sirona Appoints John Fortson as Chief Financial Officer
CHARLOTTE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of John Fortson as Executive
Read more →XRAYDentsply Sirona Continues to Expand U.S. Distribution Network to Strengthen Access to its Digital Dentistry Solutions Across Key Regional Markets
CHARLOTTE, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies, today announced the strengthening of its U.S. distribution footprint through an expanded partnership wi
Read more →XRAYDentsply Sirona to Participate in the 2026 Stifel Jaws & Paws Conference
CHARLOTTE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 2026 Stifel Jaws & Paws Conference. Management is scheduled to present on Wednesday, May 27, 2026, a
Read more →XRAYDentsply Sirona Reports First Quarter 2026 Results
Dentsply Sirona reported its Q1 2026 financial results, indicating progress in its Return-to-Growth Action Plan despite external pressures. The company is restructuring commercially and innovating its portfolio, maintaining a full-year outlook of $3.5 billion to $3.6 billion in net sales. Operating cash flow improved significantly compared to the previous year, although free cash flow remains negative.
Read more →XRAY▼ -5.2%on this newsshared move
Dentsply Sirona Launches Smart View - Detect, World’s First FDA-Cleared AI-enabled diagnostic aid for detecting teeth with Periapical Radiolucencies in CBCTs
Dentsply Sirona has launched Smart View - Detect, the first FDA-cleared AI-enabled diagnostic aid for detecting periapical radiolucencies (PARLs) in cone beam computed tomography (CBCT) scans. This innovation significantly enhances detection sensitivity and supports clearer communication between dentists and patients. Smart View - Detect will be available starting May 12, 2026, for both new and existing CBCT systems.
Read more →XRAY▼ -5.2%on this newsshared move
Dentsply Sirona Expands U.S. Distribution Footprint Through Enhanced Agreement with Atlanta Dental Supply
Dentsply Sirona has announced an enhanced distribution agreement with Atlanta Dental Supply, effective August 1, 2026. This partnership aims to strengthen Dentsply Sirona's U.S. market strategy by expanding access to its digital dentistry technologies. Atlanta Dental, a well-established distributor, will offer key products such as the CEREC system and digital imaging solutions, enhancing customer access and service.
Read more →XRAYDentsply Sirona to Host First Quarter 2026 Conference Call on May 5
Dentsply Sirona has announced an investor conference call scheduled for May 5, 2026, at 4:30 p.m. ET to discuss its first quarter financial results. The call will be accessible via a live webcast, with financial materials available on the company's investor website. A replay will also be provided post-call.
Read more →XRAYFirst-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics
Dentsply Sirona and Siemens Healthineers have announced FDA clearance for the MAGNETOM Free.Max Dental Edition, the first dental-dedicated MRI system. This innovative technology, validated through clinical trials, offers significant advantages in various dental specialties by providing non-ionizing imaging capabilities. The system enhances diagnostic confidence and is designed for efficient clinical use, with a focus on soft tissue detail.
Read more →XRAYDentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2026
Dentsply Sirona Inc. announced its participation in the upcoming Leerink Partners Global Healthcare Conference scheduled for March 10, 2026. The company's management will present at 10:00 a.m. EST, and interested parties can access the live audio webcast on their website. Dentsply Sirona is recognized as a leading manufacturer of dental products and technologies.
Read more →XRAYDentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5% Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of tax Q4 2025 adjusted EPS of $0.27
Read more →XRAYDentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors
Dentsply Sirona has appointed James Forbes and Brian McKeon to its Board of Directors, effective February 27, 2026. Forbes, a healthcare investment banker, and McKeon, a seasoned CFO, will enhance the board's strategic and financial capabilities as the company executes its Return-to-Growth action plan. Their appointments follow the recent addition of Don Zurbay to the board.
Read more →XRAYDentsply Sirona and Burkhart Dental Supply Announce Expanded Distribution Partnership to Include Dental Technology Equipment
As of April 1, Burkhart Dental Supply will represent Dentsply Sirona’s full portfolio of dental technology solutions in addition to preventive and restorative solutions it already distributes. The expanded partnership is designed to give dental professionals more comprehensive ac
Read more →XRAYDentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26
CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, February 26, 2026, at 4:30 p.m. EST to review its fourt
Read more →XRAYPatterson Dental and Dentsply Sirona Renew U.S. Dental Technology Distribution Partnership
Dentsply Sirona and Patterson Dental have renewed their U.S. dental technology distribution partnership, emphasizing a commitment to advancing dental practices through integrated technologies. This collaboration aims to enhance efficiency and patient care by providing access to a comprehensive ecosystem of dental solutions. Both companies express optimism about driving growth and innovation in the dental industry.
Read more →XRAYDentsply Sirona Appoints Donald Zurbay to Board of Directors
Dentsply Sirona has appointed Donald Zurbay to its Board of Directors, effective January 10, 2026. Zurbay, who has extensive experience in the dental and healthcare sectors, will join the Audit and Finance Committee. His addition aims to enhance the Board's capabilities in capital allocation and support the company's growth strategy. A new Growth and Value Creation Committee has also been established to oversee the company's Return-to-Growth action plan.
Read more →XRAYDentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization
Dentsply Sirona has appointed Mark R. Bezjak as Group Vice President for the Americas, effective January 28. Bezjak, a seasoned executive with over 20 years in the medical device sector, aims to enhance commercial execution and customer relationships. His experience aligns with Dentsply Sirona's strategy for growth in the dental community.
Read more →XRAYDentsply Sirona and Benco Dental Announce Expanded Partnership to Include Dental Technology Solutions
Benco Dental will offer Dentsply Sirona’s full portfolio of dental technology solutions, in addition to the consumables portfolio. Expanding the decades-long relationship reflects a shared vision to advance connected dentistry by facilitating access to an integrated ecosystem tha
Read more →XRAY▲ +6.5%on this news
Dentsply Sirona to Present at the 44th Annual J.P. Morgan Healthcare Conference
CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:0
Read more →XRAYDentsply Sirona Declares Quarterly Cash Dividend
Dentsply Sirona has announced a quarterly cash dividend of $0.16 per share, with an annual rate of $0.64. This dividend is set to be paid on January 9, 2026, to shareholders on record as of December 26, 2025. The company is recognized as a leading manufacturer in the dental products sector.
Read more →About DENTSPLY SIRONA Inc.
Headquarters13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC, 28277-3607
BIOPHARMAWATCH ELITE PLUS
Trade the next XRAY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime